JACC Vol. 62, No. 16, 2013 2013 ACCF/AHA Heart Failure Guidelines: Executive Summary October 15, 2013:1495 539 Appendix 2. Continued Reviewer Representation Employment Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness John Teerlink Content Reviewer San Francisco VA Medical Centerd Professor of Medicine  Amgen*  Anexon  CardioMEMS*  Cytokinetics  Novartis*  Scios/ Johnson & Johnson  St. Jude Medical*  Trevena None None None  Amgen*  Merck  Novartis* None Robert Touchon Content Reviewerd ACCF Prevention Committee Marshall University, Joan C. Edwards School of Medicined Professor of Medicine None None None None None None Hiroyuki Tsutsui Content Reviewer Hokkaido UniversitydProfessor of Medicine  Daiichi-Sankyo*  Novartis*  Pfizer  Takeda* None None None None None Robert Vincent Content Reviewerd ACCF Adult Congenital and Pediatric Cardiology Council Emory University School of Medicined Professor of Pediatrics None None None None  AGA None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. 